Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients



Company Remains On-Track to Report Top Line Data by End of 2Q 2024

Related Keywords

South Korea ,Australia ,United States ,Japan ,United Kingdom ,America ,Pharma Gmb ,Matt Pauls ,Savara Inc ,Drug Administration ,Linkedin ,Twitter ,Nasdaq ,Healthcare Products Regulatory Agency ,Breakthrough Therapy Designation ,New England Journal ,Promising Innovative Medicine ,Innovative Passport Designation ,North America ,Respiratory Questionnaire ,Total Score ,Component Score ,Nebulizer System ,Private Securities Litigation Reform Act ,